TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02441179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia
Description: Patients will breath 9% oxigen for 1.5 minutes interspersed with 1.5 minutes of 21% oxigen (normoxia), 15 times for a total of 45 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body weight-assisted treadmill training
Description: Patient´s gait will be trained through a weight-assisted treadmill (BWSTT). All recruited patients will start BWSTT at a speed of 0.6 km/hr. The physical therapist will manually correct posture to assure an adequate gait, increasing the speed of treadmill progressively depending upon the patient progress and tolerance. This training will be done immediately after the protocol of AIH or Sham and it will last 45 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Body weight-assisted treadmill training
Description: Patient´s gait will be trained through a weight-assisted treadmill (BWSTT). All recruited patients will start BWSTT at a speed of 0.6 km/hr. The physical therapist will manually correct posture to assure an adequate gait, increasing the speed of treadmill progressively depending upon the patient progress and tolerance. This training will be done immediately after the protocol of AIH or Sham and it will last 45 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Protocol
Description: It consists of continuous normoxia (FiO2=0.21) for 45 minutes for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks.
Study: NCT00960310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)
Study: NCT04363931

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Participants in this group received 4 weeks of manual therapy and massage of the masticatory muscles intra and extra orally together with massage of the cervical muscles. Massage and Manual Therapy brings about benefits by increasing local circulation and decreasing muscle tonus . Additionally, stretching exercises aiming to decrease pain and elongate shortened masticatory muscle fibers by autogenic inhibition of the masseter muscle were performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: Participants in this group had an application of Kinesio Taping on the masseter muscles. The material used for bruxism Kinesio Taping application was Kinesio Tex Gold Finger Prints (Kinesio Holding Corporation, Albuquerque, USA), a 100% cotton, latex-free, 5-cm wide, elastic tape. Kinesio Taping placement was chosen according to principles described by Kase et al. Tapes were cut 2.5 cm in width (cut in half vertically from 5 cm width). Two strips of Kinesio Tape were crossed over the masseter muscle area with 0-5% tension in maximum stretched epidermis position. Web-cut strips epidermis-dermis-fascia technique were used. Tape was applied bilaterally after every session of manual therapy.
Study: NCT00653887

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback
Description: 4 sessions of biofeedback one session each week

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 sessions, one each week, of discussion about anorectal disease
Study: NCT00295620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1mg tablet daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1mg tablet daily
Study: NCT02163694

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Veliparib Placebo
Description: Supplied as 40 mg, 50 mg, or 100 mg capsules for oral administration twice daily (BID) on Days -2 through 5 of a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Supplied as 40 mg, 50 mg, or 100 mg capsules for oral administration twice daily (BID) on Days -2 through 5 of a 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered intravenously over approximately 15 to 30 minutes at an area under the curve (AUC) of 6 mg/mL/min immediately following paclitaxel infusion on Day 1 of every cycle. The duration of carboplatin infusion may be lengthened according to institutional guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously over approximately 15 to 30 minutes at an area under the curve (AUC) of 6 mg/mL/min immediately following paclitaxel infusion on Day 1 of every cycle. The duration of carboplatin infusion may be lengthened according to institutional guidelines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered by intravenous infusion over approximately 1 hour at a dose of 80 mg/m² of body-surface area (BSA) on Days 1, 8, and 15 of each 21-day cycle. Paclitaxel is to be infused prior to carboplatin on Day 1. Dosing of veliparib/placebo is to be completed before the carboplatin or paclitaxel infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered by intravenous infusion over approximately 1 hour at a dose of 80 mg/m² of body-surface area (BSA) on Days 1, 8, and 15 of each 21-day cycle. Paclitaxel is to be infused prior to carboplatin on Day 1. Dosing of veliparib/placebo is to be completed before the carboplatin or paclitaxel infusions.
Study: NCT04508621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL
Description: Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patient will have the dose increased to 2 tablets for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SL Tablet
Description: Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patient will have the dose increased to 2 tablets for 12 weeks.
Study: NCT00057785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 100 mg/m\^2 intravenously on days 1, 22, and 43 and 80 mg/m\^2 intravenously on days 71, 99, and 127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 1000 mg/m\^2/day as 96-hour continuous infusion on days 71-74, 99-102, and 127-130

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy
Description: The gross tumor and lymph node metastasis, Planning Target Volume (PTV) 70 (Clinical Target Volume \[CTV\] 70 with a 5 mm margin) will receive 70 Gy in 33 fractions at 2.12 Gy per fraction. Treatment will be delivered once daily, 5 fractions per week, over 6 weeks and 3 days.
Study: NCT01636310

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Two doses of nicotine will be utilized: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Two doses of nicotine will be utilized: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
Study: NCT03856346

Intervention type: DIAGNOSTIC_TEST
Intervention: Biometry
Description: Biometry for phaco-vitrectomy procedures pre- and postoperatively
Study: NCT01494649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Test Toothpaste
Description: 0.454% stannous fluoride toothpaste

Intervention type: DRUG
Group type: OTHER
Intervention: Negative Control Toothpaste
Description: 0.76% sodium monofluorophosphate toothpaste
Study: NCT02735226

Intervention type: OTHER
Intervention: stroke network and policy intervention
Description: Shanghai stroke service and network contributes to update the ability of stroke care of comprehensive and primary stroke center,to improve radiation ability of comprehensive stroke centers and try to form a close relationship between comprehensive stroke centers and its primary stroke centers.
Study: NCT03430557

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP
Description: platelet rich plasma

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: periapical surgery without PRP
Description: retrograde MTA filling will be done after apicectomy and flap will be closed without filling anything in the bony lesion.
Study: NCT04061057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Drug: 1. Lidocaine Intravenous lidocaine bolus of 1.5mg/kg immediately after anesthesia induction followed by infusion at 2.0mg/kg/hr up to 1 hr after end of surgery.~2. Fentanyl IV infusion via PCA (patient controlled analgesia) machine of fentanyl 10 μg/ml, ramosetron 0.3 mg, normal saline, total 100 ml, infusion rate 1 ml/hr, 1 ml bolus and lockout time 7 min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Drug: 1. Normal saline Intravenous normal saline bolus of immediately after anesthesia induction followed by infusion up to 1 hr after end of surgery. Volume of normal saline is equal to lidocaine.~2. Fentanyl IV infusion via PCA (patient controlled analgesia) machine of fentanyl 10 μg/ml, ramosetron 0.3 mg, normal saline, total 100 ml, infusion rate 1 ml/hr, 1 ml bolus and lockout time 7 min.
Study: NCT02816749

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maggot debridement therapy
Description: Participant will receive bio-bags treatment every 3 days until the wound heal completely, when wounds assessed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Dressing Therapy
Description: Participant will be disinfected by iodophor and dressed by gauze 3 days until the wound heal completely, when wounds assessed.
Study: NCT00965263

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cocaine vaccine (TA-CD)
Description: TA-CD (82,360 μg; IM) were administered at weeks 1, 3, 5 and 9.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cocaine vaccine (TA-CD)
Description: TA-CD (82,360 μg; IM) were administered at weeks 1, 3, 5 and 9.
Study: NCT00861939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion HCI 300 mg Extended-Release Tablets EON

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WELLBUTRIN XL 300 mg Extended-Release Tablets GlaxoSmithKline
Study: NCT03199898

Intervention type: DIAGNOSTIC_TEST
Intervention: Silverman-Andersen Retraction Score
Description: The Silverman-Andersen Retraction Score (SAs) is used to assess severity of respiratory distress in newborn and preterm infants without respiratory support.The score comprises 4 inspiratory categories of movements (thoraco-abdominal, intercostal, xiphoid, and chin movements) and one expiratory category (grunting).

Intervention type: DIAGNOSTIC_TEST
Intervention: Silverman-Andersen Retraction Score
Description: The Silverman-Andersen Retraction Score (SAs) is used to assess severity of respiratory distress in newborn and preterm infants without respiratory support.The score comprises 4 inspiratory categories of movements (thoraco-abdominal, intercostal, xiphoid, and chin movements) and one expiratory category (grunting).

Intervention type: DIAGNOSTIC_TEST
Intervention: Silverman-Andersen Retraction Score
Description: The Silverman-Andersen Retraction Score (SAs) is used to assess severity of respiratory distress in newborn and preterm infants without respiratory support.The score comprises 4 inspiratory categories of movements (thoraco-abdominal, intercostal, xiphoid, and chin movements) and one expiratory category (grunting).
Study: NCT03013517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viaskin Peanut 250µg
Description: DBV712 250 µg, once daily
Study: NCT00893230

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic L sakei KCTC 10755BP
Description: freeze-dried, 50,0000,0000 colony-forming units, twice daily, for 12 weeks
Study: NCT00786357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NIOSH shiftwork booklet
Description: weekly readings about coping with shiftwork

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Enhancement Training System
Description: 4 week program of readings and relaxation programs
Study: NCT02811237

Intervention type: OTHER
Group type: OTHER
Intervention: HESTIA
Description: Management based on the HESTIA rule:~* If the rule is negative, meaning that patient meet none of the exclusion criteria of the rule, the proposed management will be outpatient care.~* In the other cases, the patient will receive in-hospital care.~Any reason for management (hospitalization or outpatient treatment) not based on the recommendation will be explained and documented in the e-CRF.

Intervention type: OTHER
Group type: OTHER
Intervention: sPESI
Description: Management based on the simplified PESI score:~* If the sPESI score =0, the proposed management will be outpatient care.~* In the other cases, the patient will receive in-hospital care.~Any reason for management (hospitalization or outpatient treatment) not based on the recommendation will be explained and documented in the e-CRF.
Study: NCT00893230

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: microcrystalline cellulose (placebo)
Description: freeze-dried, 50,0000,0000 colony-forming units, twice daily, for 12 weeks
Study: NCT01999322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Administered subcutaneously (s.c., under the skin). Dose individually adjusted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
Study: NCT00591292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indibulin
Description: Dose escalation of indibulin given twice daily for up to 6 months
Study: NCT00668109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 10 mg one hour prior to sexual intercourse

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: 10 mg taken approximately 24 hours prior to sexual intercourse
Study: NCT03701555

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PvP001 placebo
Description: placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PvP001 placebo
Description: placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PvP001 placebo
Description: placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PvP001 placebo
Description: placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PvP001 placebo
Description: placebo
Study: NCT00866528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: oral pazopanib once daily (Phase I starting dose 800 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel IV once every 3 weeks (Phase I starting dose 135 mg/m2).
Study: NCT00190684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atomoxetine
Description: 0.5-1.8 mg/kg/day, by mouth (PO), for up to 5 years
Study: NCT00423228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZT-1
Description: Patients in the ZT-1 treatment group will receive ZT 1-1 mg capsules administered p.o. daily during the first month of treatment, followed by ZT-1 implants (9 mg) administered s.c. during the second month of treatment, followed by ZT-1 implants (12 mg) administered s.c. every 4 weeks during months 3 to 6 of treatment. Patients in the ZT-1 treatment group will receive dummy donepezil capsules during months 2 to 6 of the treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Patients in the donepezil treatment group will receive donepezil 5 mg capsules administered p.o. during the first month of treatment, followed by donepezil 10 mg/day during months 2 to 6 of the treatment period. Patients in the donepezil treatment group will also receive s.c. injections of dummy ZT 1 implants every 4 weeks during months 2 to 6 of the treatment period.
Study: NCT02738489

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: A fully human monoclonal immunoglobulin (IgG4 subtype)
Study: NCT03701555

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PvP001 placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PvP001 100 mg
Description: PvP001 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PvP001 100 mg
Description: PvP001 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PvP001 300 mg
Description: PvP001 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PvP001 300 mg
Description: PvP001 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PvP001 300 mg
Description: PvP001 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PvP001 900 mg
Description: PvP001 900 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PvP001 900 mg
Description: PvP001 900 mg
Study: NCT02738489

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: A fully human monoclonal immunoglobulin (IgG4 subtype)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: A fully human monoclonal immunoglobulin (IgG4 subtype)
Study: NCT03701555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PvP001 900 mg
Description: PvP001 900 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maximum Feasible Dose (MFD) of PvP002
Description: MFD of PvP002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maximum Feasible Dose (MFD) of PvP002
Description: MFD of PvP002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maximum Feasible Dose (MFD) of PvP002
Description: MFD of PvP002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maximum Tolerated Dose (MTD) of PvP001
Description: Maximum Tolerated Dose (MTD) of PvP001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maximum Tolerated Dose (MTD) of PvP001
Description: Maximum Tolerated Dose (MTD) of PvP001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTD of PvP001 following 7 days of PPI treatment
Description: Maximum Tolerated Dose (MTD) of PvP001 following 7 days of PPI (Proton Pump Inhibitor) treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PvP002 placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PvP001 600 mg
Description: PvP001 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PvP003 placebo
Description: Placebo tablet orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PvP003 placebo
Description: Placebo tablet orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PvP003 placebo
Description: Placebo tablet orally.
Study: NCT02069886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deferasirox
Description: 125, 250, 500 mg dispersable tablets
Study: NCT03962660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HaRTS-TRENDS
Description: HaRTS-TRENDS comprises 4, individual sessions delivered in the context of the interventionist's pragmatic harm-reduction mindset paired with a compassionate, advocacy-oriented heart-set or style. It comprises the delivery of 4 manualized components, including a) participant-led tracking of preferred smoking outcomes, b) elicitation of participants' harm-reduction goals and their progress toward achieving them, c) discussion of the relative risks of various nicotine delivery systems, and d) instruction in using ENDS. Additionally, HaRTS-TRENDS entails provision of commercially available ENDS.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care (SC)
Description: The 4-session, individual standard care control condition entails the well-documented and evidence-based 5 As intervention (i.e., Ask about nicotine use, Assess use, Advise to quit smoking, Assist with exploring current smoking/planning smoking cessation, Arrange follow-up). Part of arranging follow-up is the recommendation to call the smoking quit line, which can supply additional counseling and nicotine replacement therapy.
Study: NCT03701555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PvP003 placebo
Description: Placebo tablet orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PvP003 placebo
Description: Placebo tablet orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PvP003 placebo
Description: Placebo tablet orally.
Study: NCT04222556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thiwáhe Gluwáš'akapi
Description: Thiwáhe Gluwáš'akapi (TG, sacred home in which family is made strong) is a cultural adaptation of the Strengthening Families Program for Parents and Youth 10-14 (SFP 10-14). TG, like SFP 10-14, is a 7-week family-based prevention program with separate youth and adult sessions followed by family sessions. Videos teach content and spark discussion; games and activities foster interaction and provide opportunities to practice skills. Four key adaptations were made to create TG: (1) cultural kinship teachings and tribal language kinship words were embedded throughout; (2) a parent session on coping with stress was enhanced to teach recognizing and responding to trauma reactions in youth; (3) a session on listening was moved earlier in the curriculum, given cultural oral tradition; (4) session videos were remade with local actors and adapted scenarios. A multiphase optimization strategy design was used to test potential adaptations, resulting in the optimized TG program.
Study: NCT03701555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PvP003
Description: PvP003 tablet orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PvP003
Description: PvP003 tablet orally.
Study: NCT04222556

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Woyute Waśte
Description: Woyute Waśte (WW) was adapted from the Colorado School of Public Health's Integrated Nutrition Education Program (INEP) for the culture and context of the reservation. Families will meet for 1 session to participate in hands-on activities - preparing healthy meals, family physical activity, and sugary drinks. They will discuss setting healthy goals and tracking progress, receive recipes and water bottles, and for 6 weeks after the session, will get text messages with additional program content.